Exelixis (NASDAQ:EXEL) Given New $40.00 Price Target at Royal Bank of Canada
Exelixis (NASDAQ:EXEL – Free Report) had its price target hoisted by Royal Bank of Canada from $38.00 to $40.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. EXEL has been the topic of a number of other reports. Barclays lifted their […]
Exelixis (NASDAQ:EXEL – Free Report) had its price target hoisted by Royal Bank of Canada from $38.00 to $40.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. EXEL has been the topic of a number of other reports. Barclays lifted their […]
